We move science to medicine because our world is MEANT FOR MORE
About Regeneron
Our mission is to use the power of science to bring new medicines to patients ... over and over again.
We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Press releases
Our leadership
Founded and led by physician-scientists, our leadership team includes Nobel Laureates and eight members of the National Academy of Sciences who guide our science-first approach.
A look back
Developing life-transforming treatments is no small feat. Decades of investment and perseverance have brought us to where we are today.
Regeneron at a glance
Honors and recognitions
5 consecutive years on the Dow Jones Sustainability World Index
7 consecutive years on the Civic 50 list of most community-minded companies in the U.S.
5 years as one of Fast Company's Best Workplaces for Innovators
IDEA Pharma: Pharmaceutical Invention Index, 2024
Human Rights Campaign Foundation: Corporate Equality Index, 2024
Newsweek: America's Most Responsible Companies, 2024
Read more about our
Relentless Innovation
Prioritizing Eye Health With the Gr8 Eye Movement
Driving awareness for serious retinal diseases among impacted groups with a patient-focused disease awareness campaign.
Hitting the “On Switch” in Hearing Loss
A novel gene therapy approach to switch on genetic drivers of hearing.
The RGC Effect: A Decade in the Making
Reflecting on the first 10 years of the Regeneron Genetics Center® (RGC), with impact far beyond what we could have imagined.
Our pursuit of scientific innovation continues to push the boundaries of science and improve our world. Hear our leaders reflect on our progress and vision for the future.
View our annual materials
Collaborate with us
We take a highly collaborative approach to science and drug development and prioritize investment in technology and innovation.
Our locations worldwide
More than 13,400 of our colleagues work across the globe with offices in 12 countries and clinical trials underway in more than 50 countries.
Get in touch
Submit a general or medical inquiry.